iECURE said it will present clinical data from its ongoing OTC-HOPE trial of ECUR-506 for neonatal-onset ornithine transcarbamylase deficiency at SSIEM. The update is informational with no efficacy/safety figures disclosed in the article. Likely limited near-term market impact until trial results are detailed.
iECURE said it will present clinical data from its ongoing OTC-HOPE trial of ECUR-506 for neonatal-onset ornithine transcarbamylase deficiency at SSIEM. The update is informational with no efficacy/safety figures disclosed in the article. Likely limited near-term market impact until trial results are detailed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
